Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism IDH1 inhibitors(Isocitrate dehydrogenase [NADP] cytoplasmic inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced biliary tract cancer | Phase 3 | China | 05 Sep 2023 | |
Hematologic Neoplasms | Phase 3 | - | - | |
Acute Myeloid Leukemia | Phase 2 | China | 10 Jul 2023 | |
Myelodysplastic Syndromes | Phase 2 | China | 10 Jul 2023 | |
Bile Duct Neoplasms | Phase 1 | China | 01 Nov 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 17 Aug 2020 | |
IDH1 Mutation Cholangiocarcinoma | Phase 1 | China | 22 Jun 2020 | |
Acute Promyelocytic Leukemia | Preclinical | China | 07 Nov 2023 |
Phase 1 | 36 | (mhaxocqfpq) = None wnyrcmhxio (txfhzfdido ) | Positive | 27 Jun 2024 |